HPV types 16/18 in correlation with colposcopy, cytology, histopathology, and frequent risk factors in the development of L-SIL and H-SIL intraepithelial lesion
Persistent infection of Human papillomavirus (HPV) is the strongest epidemiological factor associated with intraepithelial neoplasia and cervical cancer. These days, infection with Human papillomavirus is the most common type of sexually transmitted disease. In most cases, infection is asymptomatic and it remains undiagnosed. Women infected with high-risk types of the virus are at greater risk of developing severe dysplastic changes or cancer. The aim of this study was to examine the association between HPV type 16/18, cytology, colposcopy, biopsy and risk factors of developing intraepithelial lesions of low L-SIL and a high level of H-SIL. The study included 864 patients who had undergone detection of HPV type 16/18 DNA using in situ hybridization. All study participants were divided into three categories according to the presence of H-SIL, L-SIL and benign histologic findings. In the case study group that had L-SIL and H-SIL there was a significant higher percentage of HPV infection than in the group of patients with benign histologic findings. The percentage of H-SIL is highest in patients who had HR-HPV infection with types 16/18, sexual intercourse before 16 the age and two to five sexual partners. This study indicates that among the H-SIL intraepithelial neoplasia, there is a high presence of HR-HPV 16/18 related to the number of sexual partners and early sexual intercourse at a younger age as a statistically significant presence of these genotypes with L-SIL intraepithelial neoplasia.
Ferlay, Hr, Bray F, Forman D, Mathers C, Globocan P. cancer incidence and mortality worldwide: IarC Cancer Base. 2008;(10).
2.
Parkin Dm, Bray F, Chapter. The burden of HPV-related cancers. Vaccine. 2006;(3):11–25.
3.
Bosch F, Munoz N, Cj M, Shah K. The causal relation between human papillomavirus and cervical cancer. jurnal of Clinical Pathology. 2002;(4):244–65.
4.
Castle M, P, Wacholder S . Human papillomavirus and cervical cancer. Lancet. 2007;890.
5.
De Sanjosé S Q, I, Dt G, Klaustermeier Je, Lioveras B. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional survey. Lancet Oncol. 2010;1048–56.
6.
Bosch F, Burchell An, Schiffman M, Giuliano, Bruni L. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;1-K16.
7.
Plummer M, Castle M, Maucort-Boulch D P, Wheeler C, Group. a 2-year prospective study of human papilomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. Infect dis. 2007;1582–9.
8.
Moscicki, Hills N, Powell N, Hanson E. regression of low-grade squamous intraepithelial lesion in young women. Lancet. 2004;1678–83.
9.
Schlecht N, Platt Rw, Duarte-Franco E, Costa M, Prado Jc. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. Natl Cancer Inst. 2003;1336–43.
10.
Wheeler C. Natural history of human papillomavirus infections, cytoligic and histologic abnormalities, and cancer. Obset Gynecol Clin N am. 2008;519–36.
11.
Muñoz N, Castellsagué X, González A, Gissmann L. Vaccine. 2006;53.
12.
Ho G, Burk R.D, Klein S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. Natl Cancer Inst. 1995;1365.
13.
Mitrović-Jovanović A B, Nikolić B, Zamurović M, Pantić-Aksentijević S. Vojnosanit Pregl. 2011;1051.
14.
Keita N, Clifford G, Koulibaly M, Douno K, Kabba I, Haba M. HPV infection in women with and without cervical cancer in Conakry, Guinea. Br j Cancer. 2009;202.
15.
Michael P, Stanya M, Bidusa E, Reeda K, Kaplanb M, Mchalec G. Elkasa The prevalence of Hr-HPV dNa in asC-Us Pap smears: a military population study. Gynecologic Oncology. (1):82–5.
16.
Sideri M, Boveri I, Casadio C. age distribution of HPV genotypes in cervical intraepithelial neoplasia. Gynecol Oncol. 2011;510.
17.
Kulasingam Sl, Hughes Jp, Kivat N, Mao C, Ns W, Kuypers Jm K, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities. jaMa. 2002;1749.
18.
Naucler P, Turnberg W, Wadell G, Elfgren K. Human papillomavirus and Papanicualu test to screening for cervical cancer. N Engl j Med. 2007;1589–97.
19.
Ronco G, Carrozi GRP, Confortini F, M, Pd P, Mistro. Efficacy of human papillomavirus testing for the detection of invasive cervical screening (arTIsTIC): a randomized controlled trial. Lancet Oncol. 2010;249–57.
20.
Xi J, Toure P, Critehlow C, Haves P, Kivait N. Prevalence of specific types of human papillomavirus and cervical intraepithelial lesions in consecutive previously unscreened , west african women over 35 years of age. Int j Cancer. 2003;803.
21.
Trottier H, Franco E. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;
22.
Bosch F, Burchell An, Schiffman M, Ar G. de sanjose s, Brunu I. Epidemiology and natural history of human papillomavirus infections and type specific implication in cervical neoplasia. Vaccine. 2008;10.
23.
Mj K, Castle P, Lorincz. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. Natl Cancer Inst. 2005;1072–9.
24.
Kjaer S, Hogdall E, Frederksen K. The absolute risk of cervical abnormalities in high-risk human papillomaviruspositive, cytologically normal women over a 10-year period. Cancer res. 2006;10630–6.
25.
Bulk S, Bulkmans N, Berkhof. risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int j Cancer. 2007;361–7.
26.
Bekkers Rlm, Bulten J W, Van Tilburg A, Mravunac M, Cpt, Lfag M. Coexting highgrade glandular and squamous cervical lesions and human papillomavirus infections. British journal of Cancer. 2003;886–90.
27.
Correnti M, Medine F, Cavazza M, Hansen M, M. Human papillomavirus type distribution in cervical carcinoma, low-grade, and high-grade squamous intraepithelial lesions in Venezuelan women. Gynecol Oncol. 2011;527.
28.
Trottier H, Lindsay M, L, Wieting Sl Q. Persistance of an incident human papillomavirus infection and timihg of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomarkers Prev. 2009;854.
29.
Laukkanen P, Koskela P, Pukkala E, Knekt P, Lehtinen M. Time trends in incidence and prevalence of human papillomavirus type 6,11 and 16 infections in Finland. Gen Virol. 2003;2105.
30.
Cotton, Masso L, Cruickshank L, M. Lifestyle and socio-demographic factors associated with high-risk HPV infection in UK women. Br j Cancer. 2007;133–9.
31.
Epidemiological studies of Cervical Cancer. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15.461 womwn with cervical carcinoma and 29.154 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev. 2009;1060–9.
32.
Waller J M, Kj F, Wardle J. Human papillomavirus and cervical cancer: issues for biobeha-vioral and psychosocial research. ann Behav Med. 2004;68–79.
33.
Borgida E, Brekke N, Hepburn C. sex stereotypes and social judgment. Pers soc Psychol. 1980;821–31.
34.
Stanley M. Early age of sexual debut: a risky experience. Fam Plann reprod Health Care. 2009;118–20.
35.
Moscicki Ab. HPV infections in adolescents. dis. Markers. 2007;229–34.
36.
Louvanto K, Rintala M. Grenman s, syrjänen s: Incident cervical infections with high-and low-risk human papillomavirus (HPV) infections among mothers in the prospective Finnish Family HPV study. Infec dis. 2011;179.
37.
Louvanto K, Rintala M. Grenman s, syrjänen s: Genotype-specific persistence of genital human papillomavirus (HPV) infections in women followed for 6 years in the Finnish Family HPV study. Infect dis. 2010;436–44.
38.
Gonzalez-Bosquet E, Pallares L. Muñoz-almagro C. Predictive factors for the detection of CIN II-III in follow up of women with CIN I. Eur j Gynecol Oncol. 2010;369.
39.
Molano M, Van Den Brule A, Plummer M, Weiderpass E, Posso H. determinantion of clearance of Human Papillomavirus Infection in Colombian Women with normal cytology: a population-based, 5-year followup study. am j Epidemiol. 2003;486.
40.
Reich O, Ballon M. dNa cytometry as a first line method for diagnosis of cervical with respect to clinical behavior. Eur j Gynaecol Oncol. 2010;372.
41.
Yoon Jh, Yoo Sc, Kim W, Sj C, Chang K, Hs. role of HPV dNa testing for detection of High grade cervical lesions in women with atypical squamous cells of undetermined significance: a prospective study in Korean population. Eur j Gynaecol Oncol. 2009;271.
42.
Kjaer, Van Den Brule A, Paull G, Thomsen M, B. Type specific persistence of high risk human papillomavirus as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMj. 2002;572.
43.
Syrjanen K, Kulmala I, Petrovichev N, Konzachenco V, Zakharova T. Epidemiological, clinical and viral determinants of the increased prevalence of high risk human papillomavirus (HPV) infections in eiderly womwn. Eur j Gynaecol Oncol. 2008;114.
44.
Disaia P, Creasman W. Mosby Year Book, st. Louis 1997 autor za korespondenciju: dip.ecc.menadžmenta u zdravstu Vesna Paunovic, Ginekološko akušerska klinika " Narodni front. Kraljice Natalije. (5).
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
